Alector, Inc. (NASDAQ:ALEC – Free Report) – HC Wainwright issued their Q1 2025 EPS estimates for shares of Alector in a ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
H.C. Wainwright analyst Matthew Caufield initiated coverage of Immunic (IMUX) with a Buy rating and $10 price target The firm likes the ...
Gain Therapeutics, Inc. (NASDAQ:GANX – Free Report) – Research analysts at HC Wainwright lifted their FY2024 EPS ...
To access the live webcast of the fireside chat, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a ...
Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (LSE:0L35) with a Sell recommendation. As of November 21, 2024, the average one-year price ...
HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA), a commercial-stage biopharmaceutical firm primarily focusing on neurological and neuropsychiatry disorders.
H.C. Wainwright lowered the firm’s price target on Splash Beverage (SBEV) to 50c from $1 and keeps a Buy rating on the shares ...
Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Sell recommendation. As of November 21, 2024, the average one-year ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback